Skip to main content

Table 5 Echocardiographic and NT-proBNP measurements of Patients Evaluated After METTa (28 weeks)

From: Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children’s Oncology Group

Measurement Group N Mean 95% Confidence Interval for Mean P b
NT-proBNP2 All Patients 59 47.3c (36.3, 61.6)c < 0.01
LV End-Diastolic Posterior Wall Thickness Z-score All Patients 78 −0.29 (− 0.60, 0.02) 0.06
Female 30 − 0.57 (−1.04, − 0.09) 0.02
Male 48 −0.10 (− 0.50, 0.30) 0.63
End-Diastolic Septal Thickness Z-score All Patients 70 −0.84 (−1.2, − 0.48) < 0.01
Female 27 −1.20 (−1.76, −0.64) < 0.01
Male 43 −0.60 (−1.06, − 0.15) 0.01
LV Fractional Shortening Z-score All Patients 81 −0.19 (−0.54, 0.17) 0.30
Female 32 −0.46 (−1.02, 0.10) 0.10
Male 49 0.00 (−0.46, 0.47) 0.99
LV Mass Z-score All Patients 74 −0.74 (−1.06, − 0.42) < 0.01
Female 29 −1.23 (−1.71, −0.75) < 0.01
Male 45 −0.39 (−0.80, 0.01) 0.06
  1. aMETT minimal expected treatment time
  2. bIn the Z-score columns, a Z-score of 0 represents the average value for a healthy child of the same age. Each P-value for the Z-score measurements is from the two-sided hypothesis test with the null hypothesis H0: the population mean for the Z-scores is 0. (A Z-score of 0 represents the average value for a healthy child of the same age.) The P-value for NT-proBNP is from the two-sided hypothesis test with null hypothesis H0: the population geometric mean is 100
  3. cNT-proBNP is a raw score. Analysis for the NT-proBNP was done using a natural log transformation to stabilize the variance. The back-transformed NT-proBNP numbers are presented here for ease of interpretability. Due to the back transformations, these represent geometric means